PATRICIA KLASSEN, MD

Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use

Established patient office or other outpatient visit, 40-54 minutes

Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment

Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit

Established patient office or other outpatient visit, 30-39 minutes

Destruction of precancer skin growth, 1 growth

Established patient office or other outpatient visit, 20-29 minutes

Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage

Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes

Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and

Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report

Injection of drug or substance under skin or into muscle

Automated urinalysis test

Destruction of precancer skin growth, 2-14 growths

Injection, denosumab, 1 mg

Hemoglobin a1c level

Administration of pneumococcal vaccine

Administration of influenza virus vaccine

Insertion of needle into vein for collection of blood sample